Lonza to expand antibody-drug conjugate manufacturing capacity in Switzerland
07:01 AM | January 8, 2013 | Deepti Ramesh
Lonza says it plans to invest 14 million Swiss francs ($15 million) to expand antibody-drug conjugate (ADC) manufacturing capacity at the company’s site at Visp, Switzerland. Oncology therapeutics...
This information is only available to subscribers.
chemweek.com is the one stop platform for chemical news, data and analysis across all industry sectors and geographies.